{
    "ticker": "LIAF",
    "name": "LianBio",
    "description": "LianBio is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients in China and the Asia Pacific region. Founded in 2019, LianBio partners with leading global biotechnology and pharmaceutical companies to bring cutting-edge medicines to the rapidly growing healthcare markets in Asia. The company's portfolio includes a diverse range of therapeutic areas, including oncology, immunology, and rare diseases, with a strong emphasis on addressing unmet medical needs and improving patient outcomes. LianBio leverages its deep understanding of the local healthcare landscape, regulatory expertise, and strong relationships with key stakeholders to navigate the complexities of the pharmaceutical market in China. The company is committed to advancing its pipeline through strategic collaborations, clinical development, and commercial strategies tailored to the specific needs of the Asian patient population. LianBio's mission is to enhance the quality of life for patients by providing access to innovative therapies that can significantly impact their treatment journeys.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Shanghai, China",
    "founded": "2019",
    "website": "https://www.lianbio.com",
    "ceo": "Ying Huang",
    "social_media": {
        "linkedin": "https://www.linkedin.com/company/lianbio/"
    },
    "investor_relations": "https://investors.lianbio.com",
    "key_executives": [
        {
            "name": "Ying Huang",
            "position": "CEO"
        },
        {
            "name": "Yongzhen Zhang",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "LianBio Oncology Drug A",
                "LianBio Oncology Drug B"
            ]
        },
        {
            "category": "Immunology",
            "products": [
                "LianBio Immunology Drug A"
            ]
        }
    ],
    "seo": {
        "meta_title": "LianBio | Innovative Biopharmaceuticals for Asia",
        "meta_description": "Explore LianBio, a biopharmaceutical company dedicated to providing innovative therapies in China and the Asia Pacific region. Learn about our mission, pipeline, and impact on healthcare.",
        "keywords": [
            "LianBio",
            "Biopharmaceuticals",
            "Oncology",
            "Immunology",
            "Innovative Therapies",
            "China Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What does LianBio specialize in?",
            "answer": "LianBio specializes in developing and commercializing innovative biopharmaceuticals for oncology, immunology, and rare diseases."
        },
        {
            "question": "Where is LianBio headquartered?",
            "answer": "LianBio is headquartered in Shanghai, China."
        },
        {
            "question": "When was LianBio founded?",
            "answer": "LianBio was founded in 2019."
        }
    ],
    "competitors": [
        "BMY",
        "AMGN",
        "GILD",
        "NVS"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRNA",
        "AZN"
    ]
}